Mersana Therapeutics, Inc. - Common Stock (MRSN)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant to enter the oncology race with its $1.4 billion acquisition of Point Biopharma Global, a company specializing in precise radioligand therapies for cancer. Earlier this year, Pfizer … Continue reading "Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race"